Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who wrote (9242)	10/1/2003 9:41:35 AM
From: Biomaven	Read Replies (2) of 52153

>>beta-Amyloid prevents excitotoxicity<< not certain how to interpret it .. Neither is anyone else in the field I suspect. <g> On another topic, Tarceva not unexpectedly failed its combo trials. But compared to Iressa in similar trials it seems to have shown at least some hints of success. But maybe those that said that combining an EGFR drug that halts cells in the G1 phase doesn't make sense when combined with a chemo drug that requires that the cell be in another phase (S or M) for efficacy. But it's still a mystery to me why this issue didn't show up in preclinical studies. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next